Last checked at 21 Feb 2023 07:00
21 February 2023
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Investor Presentation
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, announces that CEO Ajan Reginald and Executive Chairman Stephen West will give a live presentation via the Investor Meet Company platform at 2pm GMT on Wednesday 1 March 2023. The objective of the presentation will be to provide investors with a Company Update.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and can arrange to meet ROQUEFORT THERAPEUTICS via:
https://www.investormeetcompany.com/roquefort-therapeutics-plc/register-investor
Investors who already follow ROQUEFORT THERAPEUTICS PLC on the Investor Meet Company platform will automatically be invited.
ENDS
Enquiries:
Roquefort Therapeutics plc | |
Stephen West (Chairman) / Ajan Reginald (CEO) | +44 (0)20 3918 8633
|
Hybridan LLP (Joint Broker) Claire Louise Noyce
Optiva Securities Limited (Joint Broker) |
+44 (0)203 764 2341 |
Christian Dennis
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale
| +44 (0)20 3411 1881
+44 (0)20 7466 5000
|
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.
Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.
Roquefort Therapeutics' portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of:
· Midkine antibodies with significant in vivo efficacy and toxicology studies;
· Midkine RNA therapeutics with novel anti-cancer gene editing action;
· STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and
· MK cell therapy with direct and NK-mediated anti-cancer action
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.